

***PRESS RELEASE***

**Tech Ops & Outsourcing**

May 15, 2023

**Larka.**



**Larka Performs Drug  
Product CMO Sourcing  
for Juvisé  
Pharmaceuticals.**

**Larka.**

 **JUVISE**<sup>®</sup>  
*pharmaceuticals*

## Juvisé Pharmaceuticals leveraged Larka's Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products.

We are delighted to announce Larka has provided Juvisé Pharmaceuticals with its Lensource® solution—a proprietary sourcing process including 360° suppliers scanning and RFI | RFQ comparison matrixes—which led to the selection of its new Drug Product (DP) CMO partner. This sourcing process is the 40th project undertaken by Larka this year—underlining our ability to effectively spot the right-fit outsourcing partners for Biotech & Pharma companies.

### Why they chose Larka

Juvisé, a world-leading French specialty pharma company, appointed Larka to leverage Lensource® and enhance the selection of their future outsourced manufacturing partner—by performing a 99% exhaustive CMO sourcing process within 10 weeks.

Since 1993, over 500 Biotech and Pharma companies like Juvisé have trusted our broad pharma sourcing capabilities and strong track record, which include:

- **100+** CRO, CDMO, CMO and CTS sourcing projects for BioPharma companies each year
- **1500+** Contract Service Providers (CSP) monitored daily via Lensource®
- **Full Coverage** of value chain, CSP typologies and drug modalities
- **500Mn** industry data collected, processed and analysed each year

### How we helped

Larka leveraged Lensource®, a 3-phase proprietary methodology combining the unique expertise of our Pharma outsourcing specialists with advanced AI technologies—designed to provide our clients with actionable insights at a faster pace and deeper level.

#### Phase 1 - Market Scanning

360° screening & identification based on Juvisé's primary search criteria, offering a complete view of all the potential manufacturing partners.

#### Phase 2 - Capabilities Assessment | RFI

Thorough technical capabilities assessment of all the potential CMO partners identified during Phase 1—followed with a shortlist generation.

#### Phase 3 - Quotations Assessment | RFQ

Assessment of the proposal and quotations provided by the shortlisted players—leading to the generation of our Lensource® matrix, developed for optimal pricing collection, standardization and comparability.

### Contact Us

#### Adrien Chalmont

Senior Manager

+33 621 006 115

[achalmont@larka.com](mailto:achalmont@larka.com)

#### Olivier Dumortier, PhD


Subject Matter Expert

+33 626 091 148

[odumortier@larka.com](mailto:odumortier@larka.com)

Discover how  
you can leverage  
Lensource®

[VISIT WEBSITE >](#)



## **About Juvisé Pharmaceuticals**

Juvisé is a French specialty pharmaceutical company specialised in manufacturing, distributing and commercialising its own branded products in 80 countries—addressing various therapeutic areas including oncology, cardiology and neurology-psychiatry.

For more information, please visit [www.juvisepharmaceuticals.com](http://www.juvisepharmaceuticals.com)

## **About Larka**

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit [www.larka.com](http://www.larka.com)